Algernon CEO and CSO to Discuss New DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD
Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to announce that Algernon’s CEO Christopher J. Moreau and CSO Dr. Mark Williams, will be discussing the Company’s New DMT Stroke Clinical Research Program on an upcoming BioPub webcast. The webcast will be held Wednesday February 3, 2021 hosted by Dr. KSS at Noon EST. The Company invites interested shareholders, …
Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that Algernon’s CEO Christopher J. Moreau and CSO Dr. Mark Williams, will be discussing the Company’s New DMT Stroke Clinical Research Program on an upcoming BioPub webcast.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic .
Algernon PharmaceuticalsFebruary 1, 2021 GMT
VANCOUVER, British Columbia, Feb. 01, 2021 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has established a clinical research program for the treatment of stroke focused on AP-188 (“N,N-Dimethyltryptamine or DMT”), a known psychedelic compound that is part of the tryptamine family (other drugs in the tryptamine family include psilocybin and psilocin). Algernon plans to be the first company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021.
Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants
Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company is pleased to provide a final summary of the common share purchase warrants of the Company that were issued on November 1, 2019. The Company elected to exercise its acceleration right under the warrant indenture governing the November Warrants. Pursuant to the terms of the Indenture, the Company accelerated the expiry date of the …
Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to provide a final summary of the common share purchase warrants of the Company (the “November Warrants”), that were issued on November 1, 2019.
Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to announce that the external Data and Safety Monitoring Board has completed its latest review of the Phase 2b part of the Company’s Phase 2b3 human study of NP-120 for the treatment of COVID-19, and has provided approval for the Company to continue on with the Phase 3 part of the study. The DSMB is a committee of .